drugset
drugset / Trial / NCT07661056

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

NCT07661056 ↗

Phase 3 Recruiting 300 enrolled Biohaven Therapeutics Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

Timeline

Start
2026-06-26
Primary completion
2028-01
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BHV-1300 Unknown — Subcutaneous

Indications

Graves disease